Literature DB >> 20031850

JUPITER: a few words of caution.

Viola Vaccarino1, J Douglas Bremner, Mary E Kelley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20031850      PMCID： PMC2798141          DOI： 10.1161/CIRCOUTCOMES.109.850404

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN： 1941-7713


× No keyword cloud information.
  15 in total

1.  Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

Authors:  Bodil Als-Nielsen; Wendong Chen; Christian Gluud; Lise L Kjaergard
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272

2.  Disseminating innovations in health care.

Authors:  Donald M Berwick
Journal:  JAMA       Date:  2003-04-16       Impact factor: 56.272

Review 3.  Actual causes of death in the United States, 2000.

Authors:  Ali H Mokdad; James S Marks; Donna F Stroup; Julie L Gerberding
Journal:  JAMA       Date:  2004-03-10       Impact factor: 56.272

Review 4.  Randomized trials stopped early for benefit: a systematic review.

Authors:  Victor M Montori; P J Devereaux; Neill K J Adhikari; Karen E A Burns; Christoph H Eggert; Matthias Briel; Christina Lacchetti; Teresa W Leung; Elizabeth Darling; Dianne M Bryant; Heiner C Bucher; Holger J Schünemann; Maureen O Meade; Deborah J Cook; Patricia J Erwin; Amit Sood; Richa Sood; Benjamin Lo; Carly A Thompson; Qi Zhou; Edward Mills; Gordon H Guyatt
Journal:  JAMA       Date:  2005-11-02       Impact factor: 56.272

5.  Ethical issues in stopping randomized trials early because of apparent benefit.

Authors:  Paul S Mueller; Victor M Montori; Dirk Bassler; Barbara A Koenig; Gordon H Guyatt
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

Review 6.  Early stopping of randomized clinical trials for overt efficacy is problematic.

Authors:  Dirk Bassler; Victor M Montori; Matthias Briel; Paul Glasziou; Gordon Guyatt
Journal:  J Clin Epidemiol       Date:  2008-03       Impact factor: 6.437

7.  An assessment of clinically useful measures of the consequences of treatment.

Authors:  A Laupacis; D L Sackett; R S Roberts
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

8.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

Review 9.  Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association.

Authors:  Harmon Eyre; Richard Kahn; Rose Marie Robertson
Journal:  Diabetes Care       Date:  2004-07       Impact factor: 19.112

10.  From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.

Authors:  Erica S Spatz; Maureen E Canavan; Mayur M Desai
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-01-13
View more
  3 in total

1.  Biomarkers: hopes and challenges in the path from discovery to clinical practice.

Authors:  Nikolaos G Frangogiannis
Journal:  Transl Res       Date:  2012-02-14       Impact factor: 7.012

Review 2.  Long non-coding RNA ANRIL in gene regulation and its duality in atherosclerosis.

Authors:  Jie-Shan Chi; Jian-Zhou Li; Jing-Jing Jia; Ting Zhang; Xiao-Ma Liu; Li Yi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

Review 3.  Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2010-12-09       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.